Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) 3-Year Book Growth Rate : 1.00% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co 3-Year Book Growth Rate?

Shenzhen Hepalink Pharmaceutical Group Co's Book Value per Share for the quarter that ended in Mar. 2024 was ¥8.22.

During the past 12 months, Shenzhen Hepalink Pharmaceutical Group Co's average Book Value per Share Growth Rate was -2.50% per year. During the past 3 years, the average Book Value per Share Growth Rate was 1.00% per year. During the past 5 years, the average Book Value per Share Growth Rate was 10.80% per year. During the past 10 years, the average Book Value per Share Growth Rate was 2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Shenzhen Hepalink Pharmaceutical Group Co was 130.80% per year. The lowest was -10.50% per year. And the median was 3.10% per year.

Competitive Comparison of Shenzhen Hepalink Pharmaceutical Group Co's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shenzhen Hepalink Pharmaceutical Group Co's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Hepalink Pharmaceutical Group Co's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's 3-Year Book Growth Rate falls into.

Shenzhen Hepalink Pharmaceutical Group Co 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Shenzhen Hepalink Pharmaceutical Group Co 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (SZSE:002399) » Definitions » 3-Year Book Growth Rate

Traded in Other Exchanges

09989:Hong Kong

Address

No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057

Website

https://www.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.

Executives

Zhang Ping	Director
Li Li	Director
Kong Yun	Executives
Li Tan	Directors, executives

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Headlines

No Headlines